The company is a high-tech biopharmaceutical listed company. The company only develops innovative drugs with significant technical advantages or market advantages (including traditional Chinese medicines or natural medicines, stem cell drugs) or products and new medical devices with similar medicinal functions, and independently develops, invests in, or mergers and acquires technologies, products, or enterprises that meet these standards. It has a market position including but not limited to patent protection, which is the company's basic product development strategy. The company is a high-tech biopharmaceutical enterprise specializing in R&D, production and sales of products for the diagnosis and treatment of allergic diseases. The company's products include dust mite drops (Sinopharm standard S20060012, trade name: Changdi), Artemisia artemisia pollen adaptogen sublingual drops (Sinopharm standard S20210001, product name: Chang Hao), dust mite skin prick diagnostic kit (Sinopharm standard S20080010, product name: Changdian), house dust mite skin prick diagnostic kit (Sinopharm standard S20190022, product name: Changdi), Artemisia artemisia pollen allergen skin prick solution (Sinopharm standard 202S30024) Birch pollen allergen skin prick solution (Chinese medicine standard) S20230023), Humulus pollen allergen skin piercing solution (Sinopharm standard S20230025). The company has received honors such as National High-tech Enterprise, Deqing County's “Top Ten” Enterprise Science and Technology Workers, Huzhou City's “365” Outstanding Innovation Team, and the Deqing County Government Quality Award.
No Data